Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) insider Michael Geffner sold 1,160 shares of the company's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $17.24, for a total value of $19,998.40. Following the transaction, the insider directly owned 224,210 shares in the company, valued at $3,865,380.40. This represents a 0.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Michael Geffner also recently made the following trade(s):
- On Wednesday, April 23rd, Michael Geffner sold 2,349 shares of Immunovant stock. The stock was sold at an average price of $14.79, for a total value of $34,741.71.
Immunovant Trading Up 3.6%
Shares of Immunovant stock traded up $0.63 during trading hours on Friday, reaching $18.13. The stock had a trading volume of 1,272,861 shares, compared to its average volume of 1,220,771. The firm has a 50 day simple moving average of $15.44 and a two-hundred day simple moving average of $18.24. The firm has a market capitalization of $3.10 billion, a price-to-earnings ratio of -6.62 and a beta of 0.63. Immunovant, Inc. has a 1 year low of $12.72 and a 1 year high of $34.47.
Immunovant (NASDAQ:IMVT - Get Free Report) last released its quarterly earnings data on Thursday, May 29th. The company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.08. The firm had revenue of $0.16 million during the quarter. During the same quarter last year, the business posted ($0.52) EPS. Sell-side analysts forecast that Immunovant, Inc. will post -2.69 EPS for the current year.
Analyst Ratings Changes
A number of research firms have commented on IMVT. UBS Group reiterated a "neutral" rating and set a $17.00 target price (down from $38.00) on shares of Immunovant in a research report on Tuesday, April 22nd. HC Wainwright reiterated a "buy" rating and set a $51.00 target price on shares of Immunovant in a research report on Wednesday, March 19th. Guggenheim reiterated a "buy" rating on shares of Immunovant in a research report on Thursday, March 20th. Bank of America decreased their target price on Immunovant from $38.00 to $33.00 and set a "buy" rating on the stock in a research report on Thursday, March 20th. Finally, The Goldman Sachs Group upgraded Immunovant to a "hold" rating and set a $18.00 price objective on the stock in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Immunovant has a consensus rating of "Moderate Buy" and a consensus target price of $36.30.
Check Out Our Latest Analysis on IMVT
Institutional Investors Weigh In On Immunovant
Several hedge funds have recently modified their holdings of IMVT. Mirae Asset Global Investments Co. Ltd. grew its stake in Immunovant by 21.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the company's stock valued at $109,000 after purchasing an additional 1,037 shares in the last quarter. Swiss National Bank grew its stake in Immunovant by 1.2% during the 4th quarter. Swiss National Bank now owns 100,800 shares of the company's stock valued at $2,497,000 after purchasing an additional 1,200 shares in the last quarter. Sei Investments Co. grew its stake in Immunovant by 4.0% during the 4th quarter. Sei Investments Co. now owns 40,456 shares of the company's stock valued at $1,002,000 after purchasing an additional 1,541 shares in the last quarter. Strs Ohio acquired a new stake in Immunovant during the 1st quarter valued at approximately $27,000. Finally, Banque Pictet & Cie SA grew its stake in Immunovant by 1.3% during the 1st quarter. Banque Pictet & Cie SA now owns 147,397 shares of the company's stock valued at $2,519,000 after purchasing an additional 1,917 shares in the last quarter. 47.08% of the stock is currently owned by hedge funds and other institutional investors.
About Immunovant
(
Get Free Report)
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immunovant, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunovant wasn't on the list.
While Immunovant currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
